SEC Form 4 · accession 0001179022-19-000019
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard E Uihlein
Director · 10% Owner
Period of report
Jan 16, 2019
Accepted (ET)
Jan 18, 2019 · 5:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 16, 2019 | A | 7,415 | $4.72 | A | 2,535,289 | D | |
| Common StockF3 | holding | — | — | — | 20,000 | I | By Ed Uihlein Family Foundation |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $4.72 | Jan 16, 2019 | A | 40,000 | A | — | Jan 16, 2029 | Common stock | 40,000 | 40,000 | D |
Explanation of responses
- F1These restricted shares were issued in lieu of cash retainer and meeting fees of $35,000 for 2019. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2019.
- F2The options vest 100% on January 16, 2020.
- F3The reporting person is president and director of Ed Uihein Family Foundation, a not-for-profit corporation. The reportion person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for purposes of Section 13(d) of the Securities Exchange Act of 1934.